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Pharmacy (medication) use among adults in 
the MA DDS population 
 
DDS Medication Review Committee 
• Clinical Reviews 
• Population analyses 
• Training  
 
Medicaid pharmacy claims analyses (2012)  
• Study design and validation.  
•  Initial results from analysis of data match.  
 
Pharmacotherapy is a common 
intervention in people with IDD  
In MA DDS population analysis, 62% were receiving 
one or more psychotropic medication 
(Rate was 47% when anticonvulsants removed) 
 
MA DDS (January 2003 Snapshot ; n=16,212 adults) 
4 
Rank Brand Name Class 
# of 
Prescriptions 
1 Depakote Anticonvulsant 18181 
2 Risperdal Atypical Antipsychotic 16756 
3 Levoxyl Thyroid hormone 12181 
4 Zyprexa Atypical Antipsychotic 11175 
5 Carbamazepine Anticonvulsant 10743 
6 Zoloft Antidepressant 9989 
7 Neurontin Anticonvulsant 8678 
8 Clonazepam Anticonvulsant 8261 
9 Celexa Antidepressant 7839 
10 Lorazepam Anxiolytic 7112 
Top 10 Rx’s to ‘DMR’ Population over 7 
months (2002-2003) 
5 
Top 11-20 Rx’s to ‘DMR’ Population over 7 mo. 
Rank Brand Name Class 
# of 
Prescriptions 
11 Lipitor Cholesterol 6942 
12 Phenobarbital Anticonvulsant 6939 
13 Fluoxetine HCl Antidepressant 6871 
14 Trazodone HCl Antidepressant 6715 
15 Phenytoin Na Ext Anticonvulsant 6519 
16 Buspirone HCl Anxiolytic 6460 
17 Paxil Antidepressant 6253 
18 Dilantin Anticonvulsant 5989 
19 Seroquel Atypical Antipsychotic 5975 
20 Protonix Ulcer/Reflux Disease 5784 
NCI: ‘Takes medication for 
behavior problems’ (2008-2009) 
Massachusetts All 20 Participating 
States 
21% 24% 
NCI: ‘Takes medication for 
anxiety’ (2008-2009) 
Massachusetts All 20 Participating 
States 
35% 
25% 
MA DDS analysis (2005): 
 
•Avg.  2.75 psychotropic 
medications (including 
anticonvulsants)  
 
•61% receiving anticonvulsants 
also received 1 or more other 
psychotropic medication 
 
•40% of those on anticonvulsants 
receive 2 or more types of 
anticonvulsants concurrently 
 
 
 
Polypharmacy is also common 
9 
Psychotropic Medications per Person over 1 month 
# of 
Psychotropics 
# of 
people 
% of 
population 
0 4618 28.5% 
1 3117 19.2% 
2 2939 18.1% 
3 2344 14.5% 
4 1508 9.3% 
5 907 5.6% 
6 456 2.8% 
7 193 1.2% 
8 72 <1% 
9 26 <1% 
10 19 <1% 
>10 13 <1% 
Range:  0-11 psychotropic 
medications 
Psychotropic medication use 
increases risk of health complications 
• Weight gain 
• Abnormal glucose metabolism (diabetes) 
• Cardiovascular disturbances 
• Oral health issues 
• Extra pyramidal symptoms, TD. 
 
Lunsky & Elserafi (2011) Research in Developmental Disabilities 
Prescribers are not always well 
prepared to treat the IDD population 
  Majority of  medical care from 
community health care providers. 
 
  Communication difficulties 
may challenge ability to monitor 
response to medication.  
 
  Complex medical picture can 
result in multiple prescribers.  
 
  2004 CAN survey: 53% of 
medical school deans did not feel 
their graduates were competent 
to treat people with N/ID. 
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The more practitioners prescribing,
the more psychotropic medication
received!
MA analysis of prescribers (2005) 
• 50% of prescribers of 
psychotropics were 
generalists 
 
• 2,637 practitioners 
prescribed non-anticonvulsant 
psychotropics  
 
More prescribers = More meds ! 
MA DDS Behavioral Supports 
Current initiatives include: 
Positive Behavioral Supports (PBS) 
training and interventions 
Updated curriculum re. restraints 
Medication Review Committee 
Clinical Review 
Provider Outreach  
Training and Continuing Education  
Analysis of Health 
Care and Claims 
Records 
Membership:   
PhD psychologists (behaviorists) 
Psych. clinical nurse specialist (CNS) 
Clinical Pharmacist 
Internist (MD) 
Gerontologist (MD)  
Neurologist (MD) 
Psychiatrist (MD)  
RNs and NP 
Hospitalist (MD) 
* All with significant experience treating adults with IDD 
 
Complex Case Consultation available through 
referral to the Med. Review Committee 
 Referral through regional offices 
 Treatment team invited to participate 
 Average 2 reviews per meeting 
 Results sent to regional/area office with request to 
forward to provider 
 Direct consult with health care provider when 
requested. 
Clinical Reviews – impressions:  
 
 Complicated intersection of behavioral and physical 
issues (e.g. pain) 
 Earlier signs of age-related issues (dementia, 
changes in drug metabolism) 
 Practitioners struggling with prescribing in a 
community setting (caregiver issues, hesitancy to 
titrate)  
Professional-to-professional outreach from team has 
included direct consultation, phone consultation. 
 
Clinical Reviews:  
One year follow up 
Of those who were reviewed with recommendation to 
remove medications – general improvement in function 
and impression of avoided psychiatric events. 
 
Where recommendations were not followed, individual 
continued to do poorly. 
 
As a group, those who were identified with emerging 
dementia showed continued decline in function.  
 
Medication Review Committee 
guides DDS outreach to prescribers 
Analyses of DDS Health Care Records to identify ‘top 
prescribers’ (regionally, by medication, specialty) 
 Example: identified 191 psychiatric prescribers: 4+ non PRN 
psychoactive meds in 2012 (11 prescribers serving 15 – 40 people) 
 
Letter sent to prescribers offering consult from clinical 
pharmacist. 
 Clinical pharmacist followed up by phone/in person. 
2012 Analysis of Medicaid Pharmacy 
Claims Data is underway 
Provides information on a larger, more diverse 
DDS population. 
 
Evaluating the methodology (data match, using 
Medicaid claims data) in light of new 
policy/funding models related to pharmacy.  
 
Several recent policy changes may  influencing 
prescription and claims patterns  in the DDS 
population 
Massachusetts Health Reform 
MassHealth Pharmacy Intiatives 
MMA - Medicare Part D  
Dual eligible population (~ 65% of adults served) 
Change in formulary (e.g. benzodiazepines) 
Affordable Care Act – duals integration efforts 
Medicaid Managed Care 
Patient Centered Medical Homes (for adults) 
 
MassHealth payment claims 
analysis – preliminary questions 
How many adults will the the dataset ‘match’ 
methodology identify? 
 
Is Medicaid claims data analysis feasible, since 
duals would only have record of co-pays (if 
they are claimed by pharmacies)? 
 
Linked dataset DDS- MassHealth 
• Timeline: ~ 10+ months from initial data request for 
inter-agency data sharing 
• Of 20,346 people eligible for Medicaid (from DDS), 
15,069 (74%) had 1 or more paid drug claim during 
the 7 month period.   
 Adults without claims include:  
• not on any medications 
• private insurance coverage 
•  dually eligible and had a prescription filled at a pharmacy that did 
not submit for the small Medicaid co-pay. 
• Nursing home, ICF/MR, incarcerated. 
Analysis plan and next steps 
• Finalize data validation 
• Analysis of individual and provider-level prescriptions 
patterns.  
• Targeted outreach to providers whose prescription 
patterns vary substantially from accepted practice 
(guidelines). 
• Identify individuals who may be in need of medication 
review.  
• Evaluate prescribing practices across service settings for 
the purpose of planning broader training or outreach 
interventions.  
 
Conclusion 
Massachusetts DDS is pursuing a multi-level 
approach to ensuring medications are used 
appropriately to support behavioral needs.  
 
Multidisciplinary team provides expertise for 
both individual review and for systems’ level 
interventions.  
 
Analysis of of claims data and health records 
allows targeted outreach.   
 
Contacts: 
 
DDS Medication Review Committee 
janice.o’keefe@state.ma.us 
 
2012 CDDER Pharmacy Analysis  
alexandra.bonardi@umassmed.edu 
